Chemours (NYSE:CC) Given New $15.00 Price Target at Royal Bank Of Canada

Chemours (NYSE:CC - Get Free Report) had its price target increased by investment analysts at Royal Bank Of Canada from $14.00 to $15.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an "outperform" rating on the specialty chemicals company's stock. Royal Bank Of Canada's target price points to a potential upside of 17.88% from the company's current price.

Several other analysts have also recently issued reports on the company. Mizuho set a $15.00 price objective on Chemours in a report on Tuesday, April 15th. UBS Group cut their target price on Chemours from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Morgan Stanley cut their target price on Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a research report on Monday, May 12th. The Goldman Sachs Group cut their target price on Chemours from $21.00 to $14.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 14th. Finally, Barclays cut their target price on Chemours from $16.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, May 28th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Chemours currently has an average rating of "Hold" and an average price target of $17.33.

Chemours Price Performance

Shares of CC traded down $0.01 during mid-day trading on Thursday, hitting $12.73. 3,221,029 shares of the stock were exchanged, compared to its average volume of 2,461,578. The company has a market cap of $1.90 billion, a PE ratio of 63.63 and a beta of 1.65. Chemours has a 52-week low of $9.13 and a 52-week high of $25.54. The firm has a 50-day moving average of $11.27 and a two-hundred day moving average of $14.05. The company has a debt-to-equity ratio of 7.01, a quick ratio of 0.83 and a current ratio of 1.75.

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.06). The firm had revenue of $1.37 billion for the quarter, compared to analysts' expectations of $1.36 billion. Chemours had a return on equity of 23.82% and a net margin of 0.54%. The firm's revenue was up .4% on a year-over-year basis. During the same period last year, the company earned $0.32 earnings per share. On average, equities analysts predict that Chemours will post 2.03 earnings per share for the current year.

Insider Buying and Selling at Chemours

In other news, insider Damian Gumpel purchased 13,400 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were acquired at an average price of $9.22 per share, with a total value of $123,548.00. Following the transaction, the insider owned 123,879 shares of the company's stock, valued at $1,142,164.38. This represents a 12.13% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Shane Hostetter purchased 4,450 shares of the company's stock in a transaction dated Monday, May 19th. The shares were purchased at an average cost of $11.28 per share, for a total transaction of $50,196.00. Following the transaction, the chief financial officer directly owned 59,694 shares in the company, valued at approximately $673,348.32. This represents a 8.06% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 25,672 shares of company stock worth $251,573 in the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Chemours

A number of hedge funds have recently made changes to their positions in CC. Proficio Capital Partners LLC purchased a new stake in shares of Chemours during the 4th quarter worth $334,000. Charles Schwab Investment Management Inc. raised its stake in Chemours by 6.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,302,272 shares of the specialty chemicals company's stock valued at $22,008,000 after buying an additional 73,220 shares during the last quarter. Victory Capital Management Inc. raised its stake in Chemours by 6.8% in the fourth quarter. Victory Capital Management Inc. now owns 110,311 shares of the specialty chemicals company's stock valued at $1,864,000 after buying an additional 7,052 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Chemours in the fourth quarter valued at about $2,283,000. Finally, Inceptionr LLC raised its stake in Chemours by 55.9% in the fourth quarter. Inceptionr LLC now owns 22,749 shares of the specialty chemicals company's stock valued at $384,000 after buying an additional 8,153 shares during the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.